All In Biotech

Drug Trial Radar · NCT06035354

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 427 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

427

Actual

Start

Nov 3, 2021

Primary completion

Jun 21, 2024

Study completion Jun 21, 2024

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Sep 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multicenter phase Ib/II clinical study to evaluate the safety, pharmacokinetics and efficacy of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • AK120Drug

    subcutaneous injection once a week

  • AK120Drug

    subcutaneous injection once a week

  • PlaceboDrug

    subcutaneous injection once a week.

  • AK120Drug

    subcutaneous injection every 2 weeks.

  • AK120Drug

    subcutaneous injection every 2 weeks.

  • AK120Drug

    subcutaneous injection every 2 weeks.

  • PlaceboDrug

    subcutaneous injection every 2 weeks for 16 weeks then crossover to AK120 Regimen 4 and Regimen 5.

  • AK120Drug

    subcutaneous injection every 2 weeks

  • AK120Drug

    subcutaneous injection every 2 weeks.

  • AK120Drug

    subcutaneous injection every 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase IbTime frame: Baseline to week 12
  2. Phase IbTime frame: Baseline to week 12
  3. Phase IbTime frame: Baseline to week 12
  4. Phase IbTime frame: Baseline to week 12
  5. Phase IbTime frame: Baseline to week 12
  6. Phase IITime frame: at week 16
  7. Phase II Extension StudyTime frame: Baseline to week 24

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • AkesoBio Investigative Site 2037, The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • AkesoBio Investigative Site 2036, The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • AkesoBio Investigative Site 1001, Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • AkesoBio Investigative Site 2044, Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • AkesoBio Investigative Site 2023, Xinqiao Hospital Medical University

    Chongqing, Chongqing Municipality, China

  • AkesoBio Investigative Site 2024, Chongqing Three Gorges Medical College

    Chongqing, Chongqing Municipality, China

  • AkesoBio Investigative Site 2040, Chongqing Traditional Chinese Medicine Hospital

    Chongqing, Chongqing Municipality, China

  • AkesoBio Investigative Site 2052, The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • AkesoBio Investigative Site 2038, The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • AkesoBio Investigative Site 2022, Dongguan People's Hospital

    Dongguan, Guangdong, China

  • AkesoBio Investigative Site 1002, Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • AkesoBio Investigative Site 2003, Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • AkesoBio Investigative Site 2049, The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • AkesoBio Investigative Site 2004, The First Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China

  • AkesoBio Investigative Site 2001, Affiliated Hospital of Chengde medical university

    Chengde, Hebei, China

  • AkesoBio Investigative Site 2010, Nanyang First People's Hospital National Third Class A Hospital

    Nanyang, Henan, China

  • AkesoBio Investigative Site 2051, Jingzhou Central Hospital

    Jingzhou, Hubei, China

  • AkesoBio Investigative Site 1005, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • AkesoBio Investigative Site 2046, The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • AkesoBio Investigative Site 2008, The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • AkesoBio Investigative Site 2048, The First People's Hospital of Changzhou

    Changzhou, Jiangsu, China

  • AkesoBio Investigative Site 2050, Wuxi Second People's Hospital

    Wuxi, Jiangsu, China

  • AkesoBio Investigative Site 2025, Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, China

  • AkesoBio Investigative Site 2032, The First Affiliated Hospital of Gannan Medical College

    Ganzhou, Jiangxi, China

  • AkesoBio Investigative Site 2011, Northeast International Hospital

    Shenyang, Liaoning, China

  • AkesoBio Investigative Site 2039, Shandong Provincial Dermatology Hospital

    Jinan, Shandong, China

  • AkesoBio Investigative Site 2041, Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • AkesoBio Investigative Site 1003, Shanghai Skin Disease Hospital

    Shanghai, Shanghai Municipality, China

  • AkesoBio Investigative Site 2027, Medical School of Yanan University

    Xianyang, Shanxi, China

  • AkesoBio Investigative Site 2029, West China Hospital,Sichuan University

    Chengdu, Sichuan, China

  • AkesoBio Investigative Site 2034, Chengdu Second People's Hospital

    Chengdu, Sichuan, China

  • AkesoBio Investigative Site 2013, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

    Tianjin, Tianjin Municipality, China

  • AkesoBio Investigative Site 2019, Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

  • AkesoBio Investigative Site 2043, First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • AkesoBio Investigative Site 1004, Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

  • AkesoBio Investigative Site 2006,Affiliated Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

  • AkesoBio Investigative Site 2007, Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, China

  • AkesoBio Investigative Site 2035, The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • AkesoBio Investigative Site 2009, The First Hospital of Jiaxing

    Jiaxing, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.